Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
Thursday
Outset Medical (TASE:BLWV) Inc . (NASDAQ:OM) maintained its Perform rating, according to Oppenheimer analysts, following the company’s first-quarter earnings report. Outset Medical disclosed a revenue increase of 5.6% year-over-year to $29.8 million, surpassing both Oppenheimer’s and the consensus estimates, which were $28.3 million and $27.8 million, respectively.
The company experienced its growth primarily through volume, with specifics on the average selling price (ASP) contribution remaining unclear. Recurring revenue saw a significant jump, rising 20% year-over-year to $22.7 million, positioning the company well on its trajectory to achieve a fourth-quarter run rate exceeding $100 million. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 5.69, though it’s currently burning through cash with negative free cash flow.
Outset Medical’s management has confirmed its full-year 2025 guidance, projecting revenues between $115 million and $125 million. This forecast aligns with the estimates by both Oppenheimer and the consensus, which stand at approximately $120 million. Furthermore, the share count has been updated to approximately 17.7 million following a stock split. InvestingPro analysis reveals that 4 analysts have revised their earnings upward for the upcoming period, with analyst price targets ranging from $14 to $45.
The company’s leadership highlighted the absence of observed changes in hospital or capital expenditure patterns, indicating stability in the market. Additionally, they noted that the sales transformation is progressing as planned and is expected to show results in the first half of 2025. Outset Medical also benefits from tariff exemptions, including a special exemption in addition to the one provided by the United States-Mexico-Canada Agreement (USMCA).
Despite the positive performance in the first quarter, Oppenheimer has adjusted its estimates based on the latest results and the company’s guidance for the fiscal year. The firm has previously expressed concerns about the fundamental challenges within the space, noting that the integration of GLP-1 treatments could further complicate the industry landscape.
In other recent news, Outset Medical reported its Q1 2025 earnings, revealing a significant earnings per share (EPS) loss of $3.24, which was considerably below the anticipated loss of $0.30 as projected by analysts. Despite this, the company’s revenue exceeded expectations, reaching $29.75 million compared to the forecast of $28.23 million. The company also reported a 6% year-over-year increase in revenue, driven by strong growth in product and console revenues. Additionally, Outset Medical’s gross margin improved significantly to 37.6%, reflecting the company’s strategic focus on enhancing profitability and operational effectiveness.
Outset Medical has set a revenue guidance range of $115-125 million for 2025, with plans to maintain gross margins in the high 30% range. The company aims to reduce cash usage to under $50 million for the year, a significant decrease from the $103 million used in 2024. Analyst firms like BTIG and RBC have shown interest in the company’s sales transformation and capital spending trends, with management reporting near completion of the sales transformation and no significant changes in hospital spending patterns.
CEO Leslie Trigg emphasized the company’s commitment to profitability, and CFO Nabil Ahmed reiterated the company’s financial discipline, noting expectations to use under $50 million in cash in 2025. The company’s strategic priorities include growing console revenue, increasing gross margins, and driving towards profitability. Despite challenges such as continued pressure on EPS due to strategic investments and potential fluctuations in hospital capital spending, Outset Medical remains focused on achieving its profitability targets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.